global. Hypermethylation instead has been reported to occur within discrete CpG-rich DNA segments that are normally unmethylated in healthy cells, the so-called CpG islands. 5, 6 There is now clear evidence that epigenetic reshaping of the genome greatly contributes to the initiation and progression of human malignancies. 7 In many cases, hypermethylation affects the promoter of tumor-suppressor genes. The resulting loss of tumor-suppressor function provides an obvious benefit for the development of the tumor. The effect of DNA hypomethylation on tumor promotion instead has long remained elusive. It was originally assumed that genome hypomethylation in tumors would cause the overexpression of a multitude of genes, including oncogenes, but there is little evidence for that. 8 In fact, DNA hypomethylation in tumors has been associated with transcriptional activation of an unexpectedly low number of genes, suggesting that most tissue-specific genes use regulatory mechanisms other than DNA methylation for selective repression. 3 It is now considered that the major contribution of genome hypomethylation to tumor development is the enhancement of genomic instability, 9 and that hypomethylation of retrotransposons and pericentromeric repeats is responsible for this genomic destabilization. However, many tumors with hypomethylated pericentromeric repeats do not show rearrangements in these regions. 10 It was therefore proposed that hypomethylated DNA repeats may also influence tumor development by modifying in trans the expression of crucial genes, possibly via sequestration of transcriptional regulators, changes in the subnuclear compartmentalization, or transcription of regulatory non-coding RNAs. 11 More recently, DNA hypomethylation in tumors was found to directly cause the activation of a particular group of germlinespecific genes, that rely on DNA methylation for repression in normal somatic tissues. 12 Hypomethylation of these genes, collectively termed cancer-germline (CG) or cancer-testis (CT) genes, is associated with their transcriptional activation, occurs in a wide variety of human tumor types, and correlates with overall genome hypomethylation. [13] [14] [15] Human CG genes comprise ∼50 genes or gene families, which are dispersed on several chromosomes, with a marked preference for the X chromosome. 16 They appear to exert a variety of cellular functions, and there is only little evidence that their combined activation in tumors contributes to malignant progression. 17, 18 One important consequence of the activation of CG genes in cancers is the production of tumor-specific antigens, which can trigger immune Cytosine methylation is a heritable modification of DNA in mammalian cells, and has a determinant impact on long-term gene repression and genome stability. Genomic methylation patterns, which remain generally stable in the adult, become profoundly altered in most human tumors. while discrete DNA segments become hypermethylated in cancer cells, many more sequences become hypomethylated. This review discusses our current understanding of the mechanisms that lead to DNA hypomethylation in tumors. evidence suggests that methylation losses are not random, but rather evolve into mosaic hypomethylation patterns. it is proposed that such hypomethylation patterns result from a historical event of transient DNA demethylation and that transcriptional regulators contribute to determining which regions escape remethylation and remain therefore unmethylated. Finally, possible stages of tumor development during which the transient DNA demethylation process may take place will be discussed. review review harbor defined regions with marked hypomethylation, ranging between one kilobase and several megabases in size. [38] [39] [40] The other parts of the genome showed normal methylation levels. It appears therefore that DNA hypomethylation in tumors is not randomly distributed over the genome but rather adopts mosaic patterns.
If cancer genomes undergo nonrandom losses of methylation, is it possible that tumors present specific hypomethylation patterns according to their histological origin? There is some evidence that this is the case. It appears indeed, that distinct classes of DNA repeats show preferential hypomethylation in specific tumor types. For instance, hypomethylation of juxtacentromeric Sat2 repeats is observed in stomach and breast cancer, but not in colon cancer. 41, 42 All three types of tumors display instead equal hypomethylation levels of another type of repeated element, the LINE-1 retrotransposon. 43 In bladder tumors, hypomethylation is commonly detected in LINE-1 and Alu elements, but not in the D4Z4 subtelomeric repeats. 44 More strikingly, the nonsatellite centromeric repeat NBL2, which has an intermediate methylation level in normal tissues, often becomes hypomethylated in neuroblastomas and hepatocellular carcinomas, and instead hypermethylated in ovarian carcinomas and Wilms' tumors. 45 Further evidence for the existence of differential hypomethylation patterns among distinct tumor types can be appreciated by analyzing the activation of CG genes. Thus, although CG genes tend to be co-activated in hypomethylated tumors, some of them show preferential activation in specific tumor types. 46 For instance, the frequency of activation of the TDRD1 gene is higher in prostate cancers than in melanomas, whereas the reverse is true for MAGEA1. 47 HAGE on the other hand shows frequent activation in chronic myeloid leukemias, where the expression of other CG genes is very rare. 48, 49 These observations suggest that DNA demethylation is facilitated at selected DNA regions in specific tumor types.
Clearly, DNA hypomethylation in tumors is not entirely random, but displays considerable specificity. Yet, additional genomic array-based methylation studies comparing tumors of different origins will be required, before we can evaluate to what extent hypomethylation patterns vary between individual tumor types. Similar studies may also reveal variations among tumor specimens of a given type, which could be related to tumor behavior and be exploited as prognostic markers.
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Historical DNA Demethylation Process
The recent identification of specific sequences, essentially at single-copy genes, that are commonly hypomethylated in tumors, offers new opportunities to study the mechanisms underlying this epigenetic process. CG genes in particular, are being used as model sequences to interrogate several aspects of the process of DNA demethylation in tumor cells. 37, [50] [51] [52] A seminal series of experiments has been performed with the human MAGEA1 gene, to address the following question: do cancer cells expressing MAGEA1 possess a permanent demethylation activity targeted to the promoter of this gene? Thus, genomic fragments comprising the MAGEA1 locus were methylated in vitro, and then stably transfected into several human tumor cell lines harboring rejection. Therapeutic vaccination trials directed against these antigens are underway. Of note, recent genome-wide microarray-based methylation studies confirmed that DNA methylation serves as an essential regulatory mechanism for a subset of genes with germline-specific expression. 19, 20 Besides CG genes, other single-copy genes, including metastasis-associated genes (e.g., synuclein-g/SNCG, uPA/PLAU), have been reported to undergo demethylation in tumors. [21] [22] [23] However, many of these genes show variable levels of methylation among normal somatic tissues, and an inconstant relationship between promoter methylation and gene repression. 24, 25 Although hypomethylation and hypermethylation of DNA coexist in cancers, they generally show no correlation regarding the extent to which they affect the genome. [26] [27] [28] These two opposite epigenetic alterations appear therefore to have different molecular causes. Mechanisms involved in the hypermethylation of CpG islands in tumors have been investigated in a large number of studies. Current evidence indicates that DNA hypermethylation in cancer is not solely the result of a non-specific de novo methylation process followed by selection of the most profitable pattern, 29 but involves in addition instructive mechanisms that target DNA methyltransferases to selected DNA sequences. [30] [31] [32] [33] [34] [35] The processes leading to DNA hypomethylation in tumors have been much less explored. This is likely due to the fact that hypomethylation was typically found within repeat elements, and that these were difficult to exploit in experimental studies because of confounding sequence overlaps. This obstacle however was overcome by the identification of single-copy genes, such as CG genes, which are frequently hypomethylated in tumors. The present review outlines recent advances in the understanding of the process of DNA demethylation in cancer, much of which derives from studies on CG genes. It will present evidence that, even though DNA hypomethylation is described as global, its distribution on tumor genomes is not random, but rather adopts specific patterns. A model will be proposed, where DNA hypomethylation results from a past event of transient DNA demethylation, and evolves into specific patterns according to the transcriptional regulators present in the tumor cell. As such, hypomethylation patterns would represent vestiges of a transient DNA demethylation process that occurred during the development of the tumor. Finally, particular stages of tumor development that may be associated with a process of DNA demethylation will be discussed.
Non-Random Hypomethylation Patterns in Tumors
The early demonstration that decreased DNA methylation levels in human tumors could be observed by applying HPLC analyses on total cellular DNA, led to the notion that hypomethylation affects the genome globally, perhaps randomly. 36 Later studies however, revealed that hypomethylated CpG sites in tumors are unevenly distributed over the genome. For instance, detailed methylation analyses of a 6 kilobases DNA segment encompassing a CG gene (MAGEA1), showed preferential hypomethylation of a restricted region surrounding the transcription start site of the gene in expressing tumor cells. 37 More recently, genomic array-based methylation studies revealed that tumor genomes higher frequency of marked genome hypomethylation in more advanced tumor stages. 36 Moreover, activation of CG genes is usually more frequent in metastatic tumor samples, as compared with primary tumors. 67 The prevalence of DNA hypomethylation in the later stages of some tumor types does not however necessarily reflect the existence of a persisting demethylation process. There are other plausible scenarios, which involve a transient DNA demethylation process (Fig. 1) . It is possible indeed, that a transient demethylation process, occurring at an early step of tumor development, produces a mixed population of tumor cells with varying levels of DNA hypomethylation. Cells with the most hypomethylated (and unstable) genome might be selected later to produce the more aggressive tumor cell population (Fig.  1B) . As a result, DNA hypomethylation would be better discernible in late-stage tumors samples, even though it was caused by an earlier transient demethylation event. Alternatively, the prevalence of DNA hypomethylation in advanced tumors may reflect the fact that the time point at which the transient DNA demethylation process occurs is variable among tumors. Hence, the chance that demethylation already occurred would be higher in lesions that are at a later stage of tumor development (Fig. 1C) .
an active and hypomethylated endogenous MAGEA1 gene. The results showed that the cells were unable to induce demethylation of the newly integrated MAGEA1 sequences, even after several weeks of culture posttransfection. 37 , 53 It appears therefore that the DNA demethylation process, which once resulted in MAGEA1 hypomethylation, was not preserved in the cultured human tumor cell lines. Of note, the same MAGEA1 fragments underwent efficient demethylation following transfection into mouse embryonic stem cells (mESCs), which are characterized by a high level of methylation plasticity. 53 This implies that DNA demethylation, if present, has the ability to act on the MAGEA1 fragments that were used in the transfection experiments.
Lack of a permanent DNA demethylation activity in tumor cells suggests that hypomethylation of MAGEA1 may result from a past demethylation event. Consistently, induction of a transient phase of demethylation, by antisense-mediated depletion of the DNA methyltransferase DNMT1 during several days, sufficed to convert a methylated and inactive MAGEA1 transgene into a permanently hypomethylated and active one. 54 Altogether, the studies on MAGEA1 transgenes suggest that DNA hypomethylation in tumors results from a historical event of transient DNA demethylation. There are several other observations that support the view that DNA demethylation is indeed a transient process in tumor cells. Firstly, tumor cell lines with a hypomethylated genome do not undergo further loss of DNA methylation during culturing. [55] [56] [57] Instead, cultured tumor cell lines often show a slow but consistent de novo methylation activity. 58, 59 Accordingly, DNA methyltransferases show normal (sometimes even increased) expression levels in cancer cells. [60] [61] [62] Secondly, DNA methylation studies in an isogenic model of transformation, comprising a series of human mammary epithelial cell cultures transitioning from normal to malignantly transformed, indicated that loss of DNA methylation is not a progressive process, but occurs in a stepwise fashion, with most losses occurring at the stage of acquisition of indefinite lifespan. 63 Finally, evaluation of global DNA methylation levels in colon and breast cancer tissue samples, demonstrated that DNA hypomethylation is present in the early stages of the disease, and does not progress in the later stages. 64, 65 Other available data however, have been interpreted as an indication that loss of DNA methylation increases progressively during tumor development, and results from a continuous demethylation process. 62, 66 For instance, in striking contrast to the reports on colon and breast cancer tissues mentioned above, methylation studies in various other tumor types revealed a enzyme that erases methylation marks from the DNA in a replication-independent manner. Of note, the exact nature of such demethylase enzyme remains to be unequivocally determined in animals. 69 One possibility for the acquisition of site-specific hypomethylation patterns in tumors would be that DNA demethylation, be it passive or active, operates preferentially at defined regions, while ignoring the remaining parts of the genome ( Fig. 2A and  B) . DNA-binding transcription factors, and the chromatin modifications they induce, could account for this selectivity by reducing local access of the maintenance methyltransferase activity in the case of the passive model or by favoring local recruitment of the demethylase enzyme in the case of the active model.
Targeting of DNA Hypomethylation
Evidence for mosaic patterns of DNA hypomethylation in cancer cells raises the intriguing question of how demethylation might be targeted to specific DNA sequences. As mentioned above, the molecular processes underlying DNA hypomethylation in tumors have been largely unexplored. Studies in developing embryos however, indicate that DNA demethylation can possibly occur through two distinct processes, commonly referred to as passive and active demethylation. 68 Passive demethylation results from improper preservation of methylation marks during DNA replication due to a lack of methylation maintenance activities, whereas active demethylation involves a demethylase Figure 2 . Models for the acquisition of site-specific hypomethylation at select CG genes during tumorigenesis. Targeted DNA demethylation at distinct CG genes may occur through four distinct mechanisms. (A) An active demethylase activity is recruited to select genes by DNA-bound transcriptional regulators. recruitment may occur either directly by physical interaction or indirectly via chromatin modifications. (B) Transcriptional regulators inhibit methylation maintenance locally, leading to regional replication-dependent demethylation. (C) The active demethylase acts on all parts of the genome, but its effect is counterbalanced by a global de novo methyltransferase activity, which remethylates CpG sites that became unmethylated. At defined genes however, transcriptional regulators inhibit remethylation, allowing local demethylation. (D) Methylation maintenance activities are decreased, leading to global loss of DNA methylation marks. Loss of methylation is however counteracted by a de novo methylation activity, except at select genes where transcriptional regulators inhibit remethylation. (e) Persistence of site-specific hypomethylation after the DNA demethylation phase requires the continued presence of transcriptional regulators to protect the regions against an ongoing de novo methylation activity. For sake of clarity, methyl groups at CpG sites (red dots) are shown only at the top of the bar representing DNA, even though they represent symmetrical methylation on both strands.
in most cancers, and their genes were not found to be mutated in tumor tissues. [60] [61] [62] The transient nature of the DNA demethylation process in tumor cells is in fact reminiscent of the multistep mode of tumor development, during which cells transit through varying states before acquiring their full malignancy. 79 It is possible that the DNA demethylation process is intimately linked to one of these transient cellular stages. Hereafter, we will consider several cellular states associated with tumor development, which may be connected with a process of DNA demethylation.
Senescence. Cellular senescence is a permanent arrest of cell division, which is induced by several stresses, such as the replication-dependent shortening of telomeres or the activation of oncogenes. 80 Evidence has accumulated in recent years indicating that senescence is a common barrier to the development of human tumors. 81, 82 Tumor cells however, eventually escape this proliferation block by inactivating p53 and RB pathways (two essential mediators of senescence), and by activating a mechanism of telomere maintenance. 80, 83 A possible link exists between cellular senescence and the process of DNA demethylation. Several studies indeed reported reduced DNA methylation levels in the genome of senescent human fibroblasts. 57, 84 Accordingly, DNA methyltransferase activities were found to decrease in cells approaching senescence. 85, 86 Interestingly, the process of DNA demethylation ceased in fibroblasts that escaped from senescence either spontaneously or following genetic manipulation. 57, 85, 86 These cells however retained a reduced level of genome methylation.
The molecular mechanisms underlying the process of DNA demethylation in senescent cells may involve either the progressive accumulation of the active hypophosphorylated form of RB, or the p53-dependent increase of p21. There is evidence indeed that these two mediators of senescence inhibit the action of DNMT1, the methyltransferase that normally copies DNA methylation marks onto newly synthesized strands during replication. Thus, p21 was shown to compete with DNMT1 for binding to PCNA, thereby hindering access of the DNA methyltransferase to replication sites. 87 RB on the other hand, was found to bind directly to DNMT1 and to inhibit its methyltransferase activity. 88 Moreover, RB appears to act as a transcriptional repressor of the DNMT1 gene. 89 Altogether these observations support the hypothesis that genome hypomethylation in tumors might result from the passage of pre-cancerous cells through a senescent state, during which loss of DNA methylation occurs as a result of DNMT1 inhibition. DNA methylation activities would later be restored in the cells that escape from senescence and further progress to malignancy, but, as mentioned above, hypomethylation would be maintained at multiple genomic regions by the presence of transcriptional regulators.
Hypoxia. It is widely recognized that growing tumors are exposed to hypoxia, that is a reduction in the normal level of tissue oxygen tension. 90 This is due to the development of disorganized blood vessels that provide poor blood flow to the tumor. Cancer cells probably experience hypoxia very early during malignant development, when the tumor mass is still only a Biochemical evidence of such molecular interactions is however not yet available.
There is another possible scenario for the acquisition of site-specific hypomethylation patterns, where DNA demethylation would operate indiscriminately on the entire genome, but would be partially counteracted by a more selective de novo methylation process. In this setting, only regions that escape remethylation would acquire a distinct hypomethylated state (Fig. 2C and D) . It appears indeed that de novo methylation often follows genome-wide demethylation. Such dual DNA methylation changes have been shown to occur in differentiating somatic cells and during early embryonic development. [70] [71] [72] In mammalian embryos for instance, the genome becomes demethylated very early after fertilization and then remethylated before implantation. 68 Genome remethylation occurs sometimes very soon, like in bovine embryos, where it is already apparent before the two-cell stage. 73 Certain regions of the genome, such as gene promoters, are protected against the embryonic remethylation phase, and maintain a hypomethylated state in somatic cells. Transcription factors play a pivotal role in this protection mechanism, as evidenced by studies in transgenic mice showing that immunity to methylation is lost when the binding site for such factors is destroyed by mutation. 74, 75 One way by which DNA-binding transcription factors may inhibit methylation is by sterically excluding DNA methyltransferases. 76 Another indirect way, involves the induction of active chromatin sates, such as histone acetylation or methylation of Lys 4 of histone H3, which appear to preclude DNA methylation activities. 20, 77 Of note, because histone modification can spread along the chromatin by a self-propagating process, the influence of a transcription factor can extend away from its binding site. 78 It is at present unknown which of the above-mentioned mechanisms of DNA demethylation targeting is at play in cancer cells. It is clear however that most tumor cell lines, including those with a hypomethylated genome, possess ongoing de novo methylation activities. This might be in favor of the demethylation/remethylation model. Interestingly, tumor cells that express the MAGEA1 gene were found to contain specific transcription factors that protect its 5' region against de novo methylation. 37 Hence, at least for CG genes, persistent hypomethylation in tumor cells appears to rely on the continued presence of specific transcription factors. Tissue-type differences in the content of such transcription factors may explain the preferential activation of select CG genes in specific types of tumors.
Possible Causes of the Transient DNA Demethylation Process
What is the triggering event that initiates the DNA demethylation process in cancer cells? This is still an unresolved question. Restoration or even intensification of methylation activities in tumor cell lines indicates that the DNA demethylation process cannot be the consequence of an irreversible loss of function of some essential methylation enzyme, by gene deletion or mutation. Accordingly, DNA methyltransferases are highly expressed
Conclusions and Perspectives
Genomic DNA hypomethylation was the first epigenetic alteration identified in cancer. Still, twenty-five years later, the molecular basis of this epigenetic process remains largely unknown. This is plausibly attributable to the transient nature of the DNA demethylation process and hence the impossibility to study this phenomenon in established tumor cell lines. Epigenetic marks are by definition heritable and can therefore represent footprints of a past event of reprogramming. Obviously, future studies aiming at deciphering the molecular mechanisms of DNA demethylation in tumors will require the use of cellular transformation models, either in culture dishes or in genetically controlled mice, to allow detailed analysis of the successive steps of tumor development. Such models may also be exploited to assess the impact of cellular senescence and hypoxia on DNA demethylation. Evaluation of the role of genome hypomethylation on tumor formation has so far relied on genetically modified mice that had a persistent reduction of DNMT1 levels. Although such studies demonstrated the importance of DNA hypomethylation on tumor promotion, it might be interesting to re-address this issue in a model where DNMT1 is only transiently diminished. This may be critical since, besides it role in methylation maintenance, DNMT1 appears to be essential for cell proliferation. 103 Therefore, a transient depletion of DNMT1 might be sufficient to induce genome hypomethylation, while allowing subsequent restoration of full proliferation activities.
DNA demethylation appears to affect virtually all human tumors. Understanding the molecular basis of this widespread tumor-associated phenomenon may therefore lead to an invaluable progress in our knowledge of cancer biology. Of note, genomic hypomethylation increases tumor immunogenicity, by permitting the activation of antigen-encoding CG genes. DNA demethylation must therefore be associated with a strong tumorpromoting effect that outweighs this "negative" immunogenic effect.
It appears that transcription factors contribute to determining which genomic regions will become hypomethylated in tumor cells. As such, DNA hypomethylation patterns in tumors may represent footprints of transcription factor activities. It is therefore likely that DNA hypomethylation profiles are indicative of the cellular pathways that are active in the tumor cells and hence may be exploited as prognostic indicators of aggressiveness or as predictive markers of sensitivity or resistance to particular therapies. few millimeters in diameter. Although hypoxia can lead to cell death, cancer cells develop adaptative mechanisms to survive and proliferate further. Regrettably, accompanying changes, including increased genomic instability and activation of anti-apoptotic mechanisms, strengthen the aggressive behavior of the tumor.
Two recent publications reported overall DNA methylation losses in cells that were cultured under severe hypoxic conditions. 91, 92 Consistently, examination of human tumor xenografts in mice revealed marked DNA hypomethylation in hypoxic areas. These results raise therefore the hypothesis that hypoxia may trigger a process of DNA demethylation. It was proposed that this might result from the inactivation of the enzyme methionine adenosyltransferase (MAT) during hypoxia, and the consequent deficiency in the synthesis of S-adenosylmethionine, the methyl donor in the DNA methyltransferase reaction.
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Changes in differentiation states. Cancer cells within a tumor tissue often show phenotypic heterogeneity, and this has been attributed in part to the intrinsic propensity of tumor cells to undergo changes in their differentiation states. 93 Supporting evidence comes from the observation that several oncogenes promote a state of cellular plasticity that favors lineage switching. 94 The cancer stem cell hypothesis offers another point of view, as it suggests that tumors are heterogeneous because they develop from a subpopulation of poorly differentiated stem-like cells, which both self-renew and differentiate to generate a diverse population of more committed tumor cells. 95 It is believed that in some cases, cancer stem cells arise from the transformation of normal stem cells. Of note, normal stem cells do not show global DNA hypomethylation, nor do they express CG genes. 96, 97 It is therefore unlikely that genome hypomethylation and CG gene activation in tumors simply results from the expansion of constitutively hypomethylated stem cells, as it was recently proposed. 98 Clearly, cancer cells experience changes in their differentiation state, and these involve either de-differentiation or differentiation. Central to cellular differentiation changes are epigenetic rearrangements, including modifications of DNA methylation patterns. Accordingly, global reduction in DNA methylation levels has been documented in several cellular differentiation models 70, 99, 100 and a process of DNA demethylation also appears to take place when somatic cells are induced to de-differentiate into pluripotent stem cells (iPS) by forced expression of selected pluripotency factors. 101 Likewise, it is possible that a transient demethylation process occurs in progressing tumor cells during their transition from one differentiation state to another. As such, DNA demethylation may contribute to the evolution of tumor heterogeneity, as previously proposed.
